Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Non-electric Intravenous Infusion Pump Market Size & Share 2026-2035
Report ID: GMI15662
|
Published Date: September 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Download Free PDF
Explore Our Licensing Options:
Download Free PDF
Non-electric Intravenous Infusion Pump Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Non-electric Intravenous Infusion Pump Market Size
The global non-electric intravenous infusion pump market was valued at USD 650 million in 2025 and is projected to rise from USD 681.9 million in 2026 to USD 1 billion by 2035, representing a 4.7% CAGR.
Non-electric Intravenous Infusion Pump Market Key Takeaways
Market Leader: B. Braun led with over 10% market share in 2025.
Leading Players: Top 5 players in this market include AVANOS, B. Braun, Baxter, VYGON, NIPRO, which collectively held a market share of 25% in 2025.
Historic growth of approximately 3.7% reflected established use in ambulatory chemotherapy, post-operative analgesia, and outpatient antibiotic therapy; the stronger forecast trajectory depends on continued migration of treatment beyond conventional inpatient settings.
Non-electric pumps use elastomeric pressure reservoirs or mechanical force to deliver medicines at predetermined rates without batteries, programming, or electronic alarms. That operating model is consequential where therapy must continue during travel, at home, or after same-day surgery, but it also fixes the clinical boundary of the category: these devices are suited to predetermined infusion protocols rather than rapidly titrated, continuously monitored treatment.
Cancer is the most material disease-led demand channel because multi-day regimens can require continuous ambulatory administration. IARC estimated 20.6 million new cancer cases and 9.8 million cancer deaths worldwide in 2024, and projects annual incidence to reach 34.4 million by 2050 [1]International Agency for Research on Cancer, Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries, 2026, iarc.who.int. The broader chronic-disease burden also supports demand for outpatient therapy pathways; noncommunicable diseases caused at least 43 million deaths in 2021, according to the World Health Organization .
GMI Analyst View
The market's value proposition is inseparable from care-site economics. Its growth does not depend on replacing electronic pumps in intensive care, where monitoring and dose adjustment remain indispensable. Instead, it depends on converting clinically stable treatment into a portable service model. In that setting, a pump's lack of power requirements becomes an operational advantage: it reduces equipment handling for providers and allows therapy to continue after discharge.
This creates a durable but bounded growth profile. Oncology, post-surgical pain care, and outpatient antimicrobial treatment can enlarge the addressable treatment volume, while high-acuity infusion remains structurally unavailable. Suppliers that can support pharmacy workflow, patient education, and provider distribution are therefore better aligned with the growth mechanism than suppliers competing on device price alone.
Key Drivers
Chronic disease and continuous-treatment demand
Cancer incidence expands the population requiring repeated or prolonged therapy, particularly for ambulatory chemotherapy protocols where an infusion must continue after the patient leaves the treatment site. Stable chemotherapy admixtures have been demonstrated in polyisoprene elastomeric pumps for outpatient EPOCH-regimen delivery, illustrating how device compatibility can convert a prolonged regimen into an outpatient workflow [3]Strickland S. et al., Stability of vincristine sulfate, doxorubicin hydrochloride and etoposide phosphate admixtures in polyisoprene elastomeric pump supporting transition of the EPOCH regimen to outpatient care, 2018, doi.org. This link between clinical protocol and care setting gives oncology a more direct demand mechanism than disease prevalence alone.
Surgical migration and non-opioid pain pathways
Procedure migration toward ambulatory settings changes the economics of post-operative analgesia. MedPAC reported that ambulatory surgical centers performed 6.4 million procedures for Medicare fee-for-service beneficiaries in 2023 [4]Medicare Payment Advisory Commission, Ambulatory Surgical Center Services: Status Report, January 2025, medpac.gov. In the United States, separate payment for AVANOS's ON-Q elastomeric infusion pump under the NOPAIN policy from January 2025 further improves the economic case for non-opioid pain-management protocols in hospital outpatient departments and ambulatory surgical centers .
Home infusion capacity
Home infusion converts bed capacity into a care-coordination problem, which favors portable devices that can run without electrical infrastructure. CMS established the Medicare home infusion therapy benefit effective January 2021 under the 21st Century Cures Act . In the United Kingdom, a Medway NHS virtual-ward program using Vygon's Accufuser treated 64 patients, avoided 496 bed-days, and reported approximately £160,000 in savings over its first ten months of full operation . Such programs strengthen demand when providers can standardize pharmacy preparation, patient training, and escalation procedures around fixed-rate therapy.
Cost-sensitive procurement
In emerging healthcare systems, a disposable non-electric pump avoids capital expenditure on electronic fleets and reduces dependence on charging, maintenance, and technical support. Regulatory requirements still matter: India's Medical Devices Rules, 2017 establish a central regulatory framework for medical devices, including import licensing requirements , while China's updated registration and filing provisions govern medical-device market access . The commercial advantage is therefore not the absence of regulation, but a product model that can fit lower-infrastructure delivery environments.
Key Restraints
Limited usage in high-acuity clinical settings
Non-electric pumps cannot provide the real-time dose changes, alarm functions, drug libraries, or systems connectivity required for many critical-care infusions. Flow in elastomeric systems is determined by reservoir pressure, flow-restrictor design, solution properties, and temperature; it cannot be actively adjusted once therapy begins. B. Braun identifies Easypump as a fixed-rate elastomeric system for controlled delivery in hospital and home settings .
Performance variability is a practical limitation rather than a theoretical one. A multicenter observational evaluation of elastomeric chemotherapy pumps found that slow infusion was involved in 40% of hospital disconnection cases, and more than half of those events had residual volumes greater than 10 mL at the scheduled disconnection time . The category can therefore create meaningful care-site efficiency in stable protocols, yet remains inappropriate where a patient's condition requires continuous titration or immediate intervention.
GMI Analyst View
Demand drivers expand the treatment situations that can be delivered outside a monitored bed, whereas the principal restraint excludes an entire class of treatment situations. This distinction matters: high-acuity limitations are not a temporary adoption barrier that distribution investment can eliminate. They arise from fixed-rate mechanical delivery itself.
The strongest growth opportunities consequently sit where clinical protocols are standardized and discharge creates measurable capacity or cost benefits. Oncology infusion, surgical pain management, and home-based antimicrobial treatment meet that condition more often than intensive care. Commercial success will depend on selecting those protocols carefully, demonstrating reliable use within them, and avoiding overextension into applications where electronic monitoring is clinically necessary.
Non-electric Intravenous Infusion Pump Market Segment Analysis
By Product Type
Elastomeric infusion pumps generated USD 556.9 million in 2025, representing 85.7% of market revenue, and are forecast to reach USD 905.0 million by 2035 at a 5.0% CAGR. Their lead reflects a practical combination of disposability, portability, and fixed-rate administration. Product designs vary by reservoir volume, flow setting, and infusion duration; NIPRO's Surefuser+ range, for example, uses a medical-grade isoprene balloon and is offered in multiple volumes for therapies extending from 30 minutes to seven days [5]Nipro Group, Surefuser+, nipro-group.com.
Mechanical pumps generated USD 93.1 million in 2025 and are projected to reach USD 129.6 million by 2035, at approximately 3.3% CAGR. These products retain relevance where a reusable or spring-driven delivery mechanism is preferred for defined specialty applications. Go Medical Industries markets Balloonfusor as a non-electronic elastomeric system for controlled intravenous or subcutaneous infusion, illustrating the overlap between mechanical simplicity and ambulatory-care use cases [6]Go Medical Industries Pty Ltd, Balloonfusor, gomedical.com.au.
By Application
Oncology generated USD 232.0 million in 2025, or 35.7% of market revenue, and is forecast to reach USD 388.9 million by 2035 at a 5.3% CAGR. The segment benefits from protocols in which drug stability and multi-day delivery are prerequisites for outpatient administration, rather than optional features. This is why its growth exceeds the overall market rate.
Pediatrics/neonatology accounted for USD 105.4 million in 2025 and is projected to reach USD 162.6 million by 2035 at a 4.4% CAGR. Pain management generated USD 182.4 million and is projected to grow at 4.2% CAGR, with reimbursement-supported post-surgical pathways providing a distinct commercial catalyst in the United States. Diabetes generated USD 70.0 million in 2025 and is projected to grow at approximately 5.0% CAGR. Gastroenterology totaled USD 39.7 million and is expected to reach USD 62.2 million by 2035, while other applications accounted for USD 20.6 million.
By End Use
Hospitals accounted for USD 294.6 million, or 45.3% of 2025 revenue, and are forecast to reach USD 453.3 million by 2035 at a 4.4% CAGR. Their role extends beyond inpatient administration: hospital pharmacy, oncology, anesthesia, and discharge teams often initiate the pathway that permits therapy to continue elsewhere.
Ambulatory surgical centers generated USD 198.5 million in 2025 and are projected to reach USD 334.1 million by 2035 at a 5.3% CAGR. Their faster growth reflects the need to send patients home with a predictable post-procedure treatment plan rather than maintain device infrastructure for short-duration use. Home care settings generated USD 119.1 million and are forecast to reach USD 192.8 million by 2035 at a 4.9% CAGR. Other end users accounted for USD 37.8 million.
GMI Analyst View
The segment pattern points to a common source of growth: therapy is moving to sites where the provider needs reliability and portability more than programmability. Elastomeric pumps are growing faster than the market because they align directly with that requirement, while mechanical products retain narrower roles where reuse or specialty delivery justifies their lower-growth profile.
Oncology and ambulatory surgical centers both reach 5.3% CAGR, but for different reasons. Oncology is propelled by repeated, multi-day treatment protocols, whereas surgical centers benefit from procedure migration and discharge-focused pain pathways. Suppliers should therefore avoid a single channel strategy: oncology adoption is pharmacy- and regimen-led, while surgical adoption is shaped by anesthesia practice, reimbursement, and center workflow.
Non-electric Intravenous Infusion Pump Market Regional Analysis
North America
North America generated USD 265.4 million in 2025, or 40.8% of global revenue, and is projected to grow at 3.9% CAGR. The United States reached USD 253.2 million in 2025 after USD 244.5 million in 2024, and is forecast to grow at 3.8% CAGR. Its mature home-infusion infrastructure, Medicare home-infusion benefit, and separate NOPAIN payment for ON-Q support demand, while maturity limits the region's relative growth rate. Canada is projected to grow faster, at 5.8% CAGR, as community-based treatment capacity expands.
Europe
Europe generated USD 183.3 million in 2025 and is forecast to grow at 4.5% CAGR. EU market entry is governed by Regulation (EU) 2017/745, which requires manufacturers to establish compliance with the applicable device-classification and conformity-assessment requirements before CE marking [7]European Commission, Guidance on classification of medical devices under Regulation (EU) 2017/745, ec.europa.eu. This favors suppliers able to pair product supply with sustained quality-system and regulatory support.
The United Kingdom offers a concrete example of operational adoption. Oxford University Hospitals reported 1,143 bed-days saved and approximately £360,410 in net savings over a 21-month elastomeric-pump evaluation [8]Vygon UK, Reducing patient stay with elastomeric infusion pumps: Oxford University Hospitals NHS Foundation Trust clinical study, vygon.co.uk. Germany, France, Spain, Italy, and the Netherlands remain relevant markets where outpatient and home-based models can create comparable demand, although local procurement and reimbursement conditions determine the pace of conversion.
Asia Pacific
Asia Pacific generated USD 137.7 million in 2025 and is forecast to reach USD 248.1 million by 2035, at a market-leading 6.0% CAGR. China and India combine rising treatment need with cost-sensitive procurement, while Japan, Australia, and South Korea provide more established clinical and regulatory environments. China's national registration framework applies to medical devices subject to registration and filing requirements . In India, the Medical Devices Rules, 2017 provide the governing regulatory framework for device licensing and market access .
Australia provides a regulated pathway for mechanically operated infusion systems; Go Medical Industries lists its products within its Australian infusion portfolio [6]Go Medical Industries Pty Ltd, Balloonfusor, gomedical.com.au. Across the region, the growth advantage arises from expanding care capacity and greater willingness to use a lower-infrastructure delivery method, rather than from a fundamentally different pump technology.
Latin America
Latin America generated USD 46.0 million in 2025 and is projected to grow at 5.6% CAGR. Brazil, Mexico, and Argentina represent the specified country markets. Demand is concentrated in urban hospital networks, oncology services, and developing ambulatory-care channels, where lower equipment requirements can improve the fit of non-electric systems relative to electronic alternatives.
Middle East and Africa
The Middle East and Africa generated USD 17.6 million in 2025 and is forecast to grow at 5.4% CAGR. South Africa, Saudi Arabia, and the UAE are the specified country markets. Regional demand is likely to remain concentrated in urban specialist facilities until home-infusion logistics, pharmacy preparation, and community follow-up capacity broaden beyond major healthcare centers.
GMI Analyst View
Regional growth is determined less by differences in the underlying technology than by the readiness of each health system to move treatment beyond inpatient care. North America produces the largest revenue base because reimbursement and provider infrastructure are already developed; its slower growth reflects a mature installed care model. Asia Pacific grows faster because ambulatory capacity and cost-sensitive procurement are expanding from a lower base.
Europe occupies an intermediate position: regulatory discipline can lengthen market-entry requirements, but documented virtual-ward and hospital-discharge outcomes demonstrate the economic value that portable infusion can deliver once implementation is established. The strategic implication is geographic sequencing. Suppliers need mature-market capabilities in reimbursement, clinical evidence, and quality assurance, but must also build localized distribution and procurement access in faster-growing Asian and emerging-market channels.
Non-electric Intravenous Infusion Pump Market Share & Competitive Landscape
Competition is moderately fragmented across multinational infusion-therapy suppliers and specialized manufacturers. The relevant basis of competition is not simply pump design. Fixed-rate delivery is technically mature, so procurement decisions are shaped by reliability, regulatory clearance, drug-compatibility support, clinician familiarity, pharmacy workflow, and the ability to service home and ambulatory channels.
Ambu participates in post-operative pain-management delivery through its ACTion Block Pain Pump. AVANOS holds a differentiated U.S. reimbursement position through ON-Q's NOPAIN payment eligibility [9]Avanos Medical, Inc., ON-Q Elastomeric Infusion Pump and ambIT Disposable Electronic Infusion Pump to Receive Separate Payment Under NOPAIN Act Starting January 1, 2025, November 11, 2024, avanos.com. B. Braun supplies the Easypump elastomeric range for controlled hospital and home infusion . Baxter has an established Infusor ambulatory-system portfolio . epic markets the SMARTeZ elastomeric-pump platform for ambulatory infusion applications .
Go Medical Industries supplies non-electronic infusion products for its Australian market portfolio [6]Go Medical Industries Pty Ltd, Balloonfusor, gomedical.com.au. Multimedical offers the Elaspump elastomeric pump range . NIPRO supplies the Surefuser+ product family . Technoline provides elastomeric pump systems for institutional use . VYGON's Accufuser is used across continuous-infusion applications and has documented UK virtual-ward and hospital-discharge implementations.
The competitive advantage in this market is therefore cumulative. A manufacturer must meet technical and regulatory requirements, but it also must earn protocol-level acceptance among clinicians and pharmacists. Suppliers able to support that adoption process can retain value even where device specifications are broadly comparable.
Recent Industry Developments
In February 2023, VYGON announced a partnership with University Hospital of Wales to support at-home continuous infusion for advanced heart-failure patients using the Accufuser elastomeric pump .
In October 2024, the FDA cleared Epic Medical's SMARTeZ Elastomeric Infusion Pump under 510(k) K242152 .
In November 2024, AVANOS announced that ON-Q and ambIT would receive separate payment under the NOPAIN Act beginning January 1, 2025 .
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Question(FAQ) :
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →